Dajie Tang

    Founding Partner, Chairman

    Doctor in Industrial Economics, Jinan University and Master in Monetary Banking, Xiamen University.20 years of experience in Investment & Financing, Merger & Acquisition, Industrial Integration and Corporate Management.Experience includes Vice President of Shenzhen Capital Group, Deputy General Manager of Shenzhen Airport Group and leader of several international mergers, Managing Director of Shenzhen HTI Group, Manager of the Department of Investment of E Funds Management and Director of China Southern Asset Management.He also serves as the Vice Chairman of Shenzhen Venture Capital Association, Executive Vice President of Shenzhen Science and Technology Entrepreneur Promotion Association and Part-time Professor of Southwestern University of Finance and Economics, Shenzhen Audencia Business School, Xidian University and China University of Mining and Technology.His publications include Research on the Behavior and its Market Effect of Securities-Investing Funds in China and The Management and Operation of Investment Banks throughout the World.Select Investment Cases include Mob.com (002174), Jiangsu Acetec Semiconductor (002077), Transwap Technology, Akeso Biopharma, Fapon Biotech, ImmunoVir, Inda Biotechnology and Chengdu Shuangliu International Airport, etc.


    Zhenqiang Wen

    Managing Partner

    Started to engage in venture capital investment in 2001.14 years of working experience in Shenzhen Capital Group.He was the General Manager of Shenzhen Capital Group Guaranty Corporation.Over 10 companies he invested before have successfully completed IPO process or were purchased by other listed companies. Select investment cases include Kugou Music (merged by Tencent), NetDragon Websoft (listed in Hong Kong), 91assistant (merged by Baidu), 7road.com (merged by changyou.com), 99Wuxian( listed in Australia), Dongguan Kingsun Optoelectronic (listed on Shenzhen SME Board), Handpay( merged by Heilan ), etc.

    Longgui Chen

    Risk control partner

    CPA,ACCA,CTA Degrees from the accounting department of Ocean University of China.He has in depth financial and tax professional background with a focus on risk control in the investment field. He has worked in several leading state-owned enterprises such as Cosco and Aerospace Science and Technology in China. He is responsible for auditing, accounting, financial management, financial analysis and contract auditing.

    Eric Zhu

    Managing Partner

    Lanzhou University MBA, BA from the College of Life Sciences, Xiamen University.Sixteen years of experience in a range of biomedical research fields including monoclonal antibody and vaccine development, GMP production and clinical trial management. Lead the world's first hepatitis E vaccine through GMP production.Years of experience in biomedical research and development, production management, and large pharmaceutical management. More than 5 years of experience in industrial investment and financing, familiar with capital markets and listed company management.

    Zhenhua Zheng

    Managing Partner

    Chief of Parmaceutical Sector in Jiangsu-Zhejiang-Shanghai .

    Postgraduate in Biochemistry and Molecular Biology, Xiamen University.Employment experience includes Roche R&D Center in Shanghai where he was responsible for development of therapeutic antibodies. Has considerable industrial experience and participated in the formation of several companies including Huading, Sunda Science & Tech and Jiaai Medical, etc.

    Rui Wang

    Investment Director

    Postgraduate in Healthcare Management, Hong Kong University.

    Master in Management, Macquarie University.

    Bachelor in Computer Science, Hong Kong University of Science and Technology.

    Has more than 10 years of experience in the financial services industry including medical analyst of the Ping An Global Pilot Fund (1 billion USD for Phase I biomedical investments). In the role his was responsible for investment in medical technology companies and the internal startup platform for medical technology in Ping An Group. Investment cases include a well-known medical chain in Singapore.

    Steve L.M.

    Chief Analyst(Pharmaceutical Industry)

    Postdoctoral studies in radiation oncology / Ph.D. in Microbiology, University of Chicago.Ten years of research experience in the field of oncology, participated in the implementation of several oncology projects, published three virology research papers in the international top journals; Experience in preclinical animal drug delivery model and pharmacology research at Biomodels LLC; Comprehensive understanding of drug development and both foreign and domestic patent applicatons.

    All Posts